Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity	
DIGI	TALX LIMITED	
ABN		
59 00	9 575 035	
We (the entity) give ASX the following	ng information.
`	7, 0	
Par	t 1 - All issues	
You m	ust complete the relevant sections (atta	sch sheets if there is not enough space).
1	*Class of *securities issued or	Performance Rights
	to be issued	Unlisted Options
2	Number of *securities issued or	7,500,000 Performance Rights
	to be issued (if known) or	2,500,000 Unlisted Options
	maximum number which may	

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

be issued

Performance Rights which subject to the Company Shares trading on ASX achieving a volume weighted average trading price of not less than \$0.09 for not less than 15 consecutive trading days within three years from the date of issue, the Performance Rights will automatically be capable of conversion into Shares within 6 months.

Unlisted Options exercisable at \$0.10 each on or before 30 June 2024.

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Performance Rights - No. Shares issued on vesting of Performance Rights will rank equally with the Company's Fully Paid Ordinary Shares.

Unlisted Options – No. Shares issued on exercise of Options will rank equally with the Company's Fully Paid Ordinary Shares.

5 Issue price or consideration

Nil cash consideration.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Performance Rights and Unlisted Options issued to Non-Executive Chairman, as part of his appointment to the Board.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

Yes

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

22 November 2018

6c Number of *securities issued without security holder approval under rule 7.1

7,500,000 Performance Rights 2,500,000 Unlisted Options

6d Number of *securities issued with security holder approval under rule 7.1A

1/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15-day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 48,586,929 7.1A: 57,180,182	
-	⁺ Issue dates	11 July 2019	
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	TT July 2017	
		NT 1	1.61
o	Number and talace of all	Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	596,216,785	Fully Paid Ordinary Shares
			1.0
		Number	+Class

⁺ See chapter 19 for defined terms.

9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	6,172,840	Unlisted Options exercisable at \$0.0324 on or before 1 September 2020
		6,107,755	Unlisted Options exercisable at \$0.0324 each on or before 8 September 2020
		2,700,000	Unlisted Options exercisable at \$0.0324 each on or before 8 September 2019
		8,800,000	Unlisted Options exercisable at \$0.0324 each on or before 18 September 2020
		2,000,000	Unlisted Options exercisable at \$0.22 each on or before 10 December 2023
		3,000,000	Unlisted Options exercisable at \$0.25 each on or before 10 December 2023
		4,000,000	Unlisted Options exercisable at \$0.30 each on or before 10 December 2023
		2,768,382	Unlisted Options exercisable at \$0.0847 each on or before 17 May 2022
		2,500,000	Unlisted Options exercisable at \$0.10 each on or before 30 June 2024
		9,000,000	Performance Rights, subject to performance-based vesting conditions detailed in the Company's notice of meeting dated 3 October 2018, expiring 10 December 2023
		7,500,000	Performance Rights which subject to the Company Shares trading on ASX achieving a volume weighted average trading price of not less than \$0.09 for not less than 15 consecutive trading days within three years from the date of issue, the Performance Rights will automatically be capable of conversion into Shares within 6 months.

⁺ See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company does not have a dividend policy

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of	N/A
20	acceptances or renunciations Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of *securities 34 (tick one) (a) +Securities described in Part 1 (b) All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the *securities are *equity securities, the names of the 20 largest holders of the 35 additional *securities, and the number and percentage of additional *securities held by those holders If the *securities are *equity securities, a distribution schedule of the additional 36 +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional *securities 37 Entities that have ticked box 34(b) Number of *securities for which 38 ⁺quotation is sought +Class of +securities for which 39 quotation is sought

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class
Quota	ntion agreement	<u> </u>	

C

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX 1 may quote the +securities on any conditions it decides.
- We warrant the following to ASX. 2
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted †quotation.

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

• An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Jamon Cootso

Sign here: Date: 11 July 2019

(Company Secretary)

Print name: Shannon Coates

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	487,865,628		
Add the following:	3,086,420 shares issued 7 August 2018		
 Number of fully paid ⁺ordinary securities issued in that 12-month period under an exception in rule 7.2 	19,737,295 issued 18 September 2018 100,000 shares issued 8 October 2018		
 Number of fully paid ⁺ordinary securities issued in that 12-month period with shareholder approval 	36,321,122 shares issued 15 May 2019 24,691,358 shares issued 1 July 2019		
 Number of partly paid ⁺ordinary securities that became fully paid in that 12-month period 			
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12-month period	0		
"A"	571,801,823		

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	85,770,273	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued	1,895,453 shares issued 13 May 2019	
or agreed to be issued in that 12-month period <i>not counting</i> those issued:	19,046,519 shares issued 17 May 2019	
Under an exception in rule 7.2	2,768,382 options issued 17 May 2019	
Under rule 7.1A	1,576,568 shares issued 27 May 2019	
With security holder approval under rule	1,896,422 shares issued 18 June 2019	
 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	7,500,000 performance rights issued 11 July 2019, the subject of this 3B 2,500,000 unlisted options issued 11 July 2019, the subject of this 3B	
"C"	37,183,344	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1 85,770,273		
"A" x 0.15 Note: number must be same as shown in Step 2		
Subtract "C"	37,183,344	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	48,586,929	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2-

Rule 7.1A – Additional placem	ent capacity fo	or eligible entities
Step 1: Calculate "A", the base figure fron calculated	n which the pla	acement capacity is
"A"		571,801,823
Note: number must be same as shown in Ste	p 1 of Part 1	
Step 2: Calculate 10% of "A"		
"D"		0.10
		Note: this value cannot be changed
<i>Multiply</i> "A" by 0.10		57,180,182
Step 3: Calculate "E", the amount of place already been used	ement capacity	under rule 7.1A that has
 Insert number of +equity securities issued or agreed to be issued in that 12-month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		Nil
"E"		Nil
Step 4: Subtract "E" from ["A" x "D"] to counder rule 7.1A	alculate remai	ning placement capacity
"A" x 0.10	57,180,182	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	57,180,182	
Note: this is capacity un		he remaining placement er rule 7.1A

⁺ See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013